National Health Investors Exceeds 2025 Guidance, Reports Strong Q4 Results, and Issues Positive 2026 Outlook
NHI sits 31% above its 52-week low of $66.413 on elevated volume (2.0× avg).
Summary
National Health Investors announced Q4 and full-year 2025 results, surpassing its own guidance, driven by strong operational growth and significant portfolio expansion, and provided an optimistic 2026 outlook with increased FFO and FAD guidance.
Key Events · Earnings and Guidance · NHI
-
Exceeded 2025 Guidance
The company surpassed its initial 2025 guidance for NAREIT FFO, Normalized FFO, and FAD, with Normalized FFO per diluted share reaching $4.91 for the year, up from $4.44 in 2024.
-
Strong Q4 and Full-Year 2025 Operational Growth
Normalized FFO per diluted share increased to $1.22 in Q4 2025 from $1.12 in Q4 2024, and Normalized FAD grew to $57.9 million from $52.1 million in the same period.
-
Positive 2026 Guidance Issued
Initial 2026 guidance projects NAREIT FFO and Normalized FFO per diluted share in the range of $4.94 - $4.99, indicating continued growth.
-
Significant Portfolio Expansion and Investment Pipeline
NHI invested $392.3 million in 2025, its most active year since 2016, and recently added nine SHOP properties for $105.5 million. The company also reported a robust pipeline of approximately $598.6 million in investment opportunities.
Analysis · NHI · Real Estate & Construction
National Health Investors reported strong financial results for Q4 and full-year 2025, exceeding its initial guidance for NAREIT FFO, Normalized FFO, and FAD. While GAAP net income per diluted share saw a decrease, key operational metrics like Normalized FFO and FAD showed significant year-over-year growth. The company demonstrated robust external growth with $392.3 million in investments during 2025, its most active year since 2016, and further expanded its Senior Housing Operating Portfolio (SHOP) with recent acquisitions totaling $105.5 million. Management highlighted a strong investment pipeline of over $598 million. The introduction of 2026 guidance, projecting increased FFO and FAD, indicates continued positive momentum. The company maintains a solid balance sheet with leverage below its target range and investment-grade credit ratings, positioning it well for future growth opportunities. This positive report comes as the stock is trading near its 52-week high, potentially reinforcing investor confidence in its strategic direction and operational execution.
At the time of this filing, NHI was trading at $87.00 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $66.41 to $91.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.